IRB #

STUDY00017065

Title

Lorlatinib for the Treatment of Non-Small Cell Lung Cancer Compassionate use IND

Principal Investigator

Jeremy Cetnar

Study Purpose

These patients report a very good quality of life with a good performance status and are therefore very motivated to proceed with further systemic treatments. At this time the only other standard treatments include immunotherapy or ceritinib. With regard to ceritinib, while this is a FDA approved medication there is no evidence to date which has tested its efficacy following administration of alectinib. Therefore, this would only add to toxicity without any known efficacy.

For the above reasons the use of Lorlatinib is ideal. It is an oral therapy with exquisite activity against ALK, and in particular, against brain metastases.

Medical Condition(s)

Non-Small Cell Lung Cancer

Eligibility Criteria

Please see appendices 7.1 and 7.2

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression then 30-day follow-up visit

Minors Included

No

Contact

OHSU Knight Cancer Institute Information line 503-494-1080
trials@ohsu.edu

Sponsor

Recruitment End

12/31/2030

Compensation Provided

No


Go Back